Recent developments include Mineralys acquiring full intellectual property rights to lorundrostat by terminating the license agreement with Tanabe Pharma, and ongoing clinical and financial updates from quarterly earnings calls.

• Mineralys Therapeutics terminated its license agreement and acquired full intellectual property rights to lorundrostat from Tanabe Pharma in October 2026, consolidating control over its lead product candidate [N1].
• The company held its Q2 2026 earnings call in August 2026, discussing clinical progress and financial results [N2][N3][N4].
• Mineralys reported that lorundrostat reduced heart failure risk biomarkers in hypertension trials as of June 2026 [N5].
• The company reported Q1 2026 earnings and clinical updates in May 2026 [N6].
• TD Cowen initiated coverage of Mineralys Therapeutics with a buy recommendation in April 2026 [N7].
• Q4 2025 earnings call transcript and FDA acceptance of lorundrostat NDA were reported in March 2026 [N8].

Lorundrostat's demonstrated clinical efficacy in reducing systolic blood pressure across diverse patient populations, including those with resistant hypertension and comorbid CKD or OSA, supports its potential as an innovative treatment addressing a large unmet need. The favorable safety profile and once-daily dosing convenience may enhance patient adherence and physician acceptance. The FDA's acceptance of the NDA and the company's acquisition of full IP rights provide strategic advantages. Strong liquidity positions Mineralys to support ongoing development and potential commercialization activities.

Mineralys faces risks related to regulatory approval uncertainties, including the FDA's review outcome and potential requests for additional data. The company's indebtedness under the Loan Agreement introduces financial risk, including covenant compliance and potential asset foreclosure in case of default. Tariffs on imported drug products and inflationary pressures may increase operational costs. Market competition from established antihypertensive agents and generic mineralocorticoid receptor antagonists may limit market penetration. Clinical trial results in some indications, such as OSA, showed limited efficacy on primary endpoints, which may affect broader adoption.

Mineralys Therapeutics' moat is based on its proprietary, highly selective aldosterone synthase inhibitor, lorundrostat, which targets a significant unmet medical need in hypertension driven by dysregulated aldosterone. The compound's selectivity, favorable safety profile, and clinical efficacy demonstrated in multiple trials, including pivotal Phase 3 studies, differentiate it from existing mineralocorticoid receptor antagonists that have tolerability issues. The company's acquisition of full IP rights to lorundrostat strengthens its control over the asset. The complexity of developing selective ASIs and the clinical validation required create barriers to entry for competitors. However, the company faces risks from regulatory approval processes, market adoption, and competition from established antihypertensive therapies.

• Regulatory Approval Risk: The FDA's review of lorundrostat's NDA carries uncertainty, including potential requests for additional data or delays that could impact the timing and ability to commercialize the product.
• Financial and Indebtedness Risk: The Loan Agreement entered in June 2026 imposes covenants and security interests on company assets, including intellectual property. Failure to comply could lead to default and foreclosure risks.
• Tariff and Inflation Risk: Potential tariffs on imported drug products, possibly up to 100%, and inflationary pressures may increase manufacturing and operational costs, adversely affecting financial condition.
• Market Competition Risk: Existing antihypertensive therapies, including generic mineralocorticoid receptor antagonists, present competitive challenges that may limit lorundrostat's market adoption.
• Clinical Trial Outcome Risk: While lorundrostat showed positive results in hypertension and CKD, some trials such as Explore-OSA did not meet all primary endpoints, which may affect perception and uptake.